New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 30, 2014
07:07 EDTMDWDMediWound expands distribution of NexoBrid to South Korea
MediWound announced the signing of an agreement granting BexPharm Korea exclusive rights to market and distribute NexoBrid in South Korea for the treatment of severe burns upon receipt of regulatory approval. An estimated 10,000 patients with severe burns are hospitalized every year in South Korea and primarily are treated at approximately 10 burn centers. In addition to this agreement in South Korea, MediWound has recently executed exclusive distribution agreements for NexoBrid to treat severe burns in Russia with Genfa Medica S.A. and in Argentina with Tuteur S.A.C.I.F.I.A.
News For MDWD From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
February 12, 2016
11:35 EDTMDWDMediWound management to meet with Jefferies
Subscribe for More Information
February 2, 2016
16:59 EDTMDWDMediWound says second EscharEx Phase 2 clinical trial meets primary endpoint
MediWound announces positive top-line results from the company's second Phase 2 clinical trial evaluating EscharEx for debridement of dead or damaged tissue in chronic and other hard-to-heal wounds. EscharEx is based on the same propriety proteolytic enzyme technology used in MediWound's NexoBrid, which is approved and commercially available in Europe and Israel for the removal of eschar in adults with deep partial- and full-thickness thermal burns. Effective debridement is a critical first step to facilitate wound management and is complementary to existing wound healing products, which require a clean wound bed. This trial was the second Phase 2 trial with EscharEx, following a feasibility Phase 2 trial, conducted in Israel with 24 patients that demonstrated the ability of EscharEx to debride chronic and hard-to-heal wounds of various etiologies. The objectives of this second Phase 2 trial were to evaluate the efficacy of EscharEx in debriding chronic wounds, to assess its safety and lack of deleterious effect on wound healing and to further analyze these effects in different etiologies to guide the design of future pivotal studies. The study met its primary endpoint with statistical significance. Patients treated with EscharEx demonstrated a higher incidence of complete debridement compared with patients treated with the hydrogel vehicle. The study included secondary endpoints that provide further insight on a number of efficacy and safety parameters. The secondary endpoint of time to complete debridement demonstrated a clear trend that strongly suggests that not only is there a difference in the incidence of debridement, as confirmed by the primary endpoint, but that debridement occurred earlier in the group treated by EscharEx.

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the disclaimer & terms of use